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Tumor Necrosis Factor a  Induces Endothelial Galactosyl Transferase 
Activity and Verocytotoxin Receptors. Role of Specific Tumor Necrosis
Factor Receptors and Protein Kinase C
By Nicole C.A.J. van de Kar, Teake Kooistra, Mario Vermeer, Werner Lesslauer, Leo A.H. Monnens, 
and Victor W.M. van Hinsbergh
Infections with verocytotoxin (VT) producing Escherichia 
coii have been strongly implicated in the epidemic form of 
hemolytic uremic syndrome (HUS). Endothelial damage 
plays a central role in the pathogenesis of HUS. In vitro 
studies have shown that VT can damage endothelial cells 
after interaction with its cellular receptor globotriaosylcera- 
mide (GbOse3cer). Cytokines, such as tumor necrosis factor 
a (TNFa) and interleukin-1 (IL-1) can potentiate the toxic 
effect of VT by inducing a protein-synthesis dependent in­
crease in VT receptors on endothelial cells. In this study, 
the mechanisms underlying the increase in endothelial VT 
receptors induced by TNFa were studied in more detail. To 
investigate which proteins were involved in this induction, 
endothelial cells were incubated with and without TNFa in 
the presence of ’''C-galactose or 14C-glucose. Thin-layer chro­
matography (TLC) analysis of the glycolipid extracts of these 
cells demonstrated a markedly enhanced incorporation of 
14C-galactose in GbOse3cer and other galactose-containing 
glycolipids, suggesting that TNFa enhanced galactosyl- 
transferase activity. To examine the role of the two recently 
cloned TNF-receptors (TNFR-p75 and TNFR-p55) in the 
TNFa-induced increase in GbOse3cer in human endothelial 
cells, cells were incubated with TNFa, the TIMFR-p55 selec­
tive R32W-S86T-TN Fa-mutant, or the TNFR-p75 selective 
D143N-A145R-TNFa-mutant. The effect of TNFa activation.
determined by binding-experiments with 125I-VT-1, could be 
largely, but not completely mimicked by R32W-S86T-TNFa. 
Although incubation of cells with D143N-A145R-TNF« did 
not show an increase in VT-1 binding, the monoclonal anti­
body utr-1, which prevents binding to TNFR-p75, decreased 
the TNFa-induced VT-1 binding. Activation of protein kinase 
C (PKC) by phorbol ester increases the expression of VT-1 
receptors; this effect was prevented by the PKC inhibitor 
Ro31-8220 and by homologous desensitization by pretreat­
ment with phorbol ester. In contrast, the presence of the 
protein kinase inhibitor Ro31-8220 or desensitization of PKC 
activity reduced the TNFa-induced increase in VT-1 recep­
tors maximally by 50% and 24%, respectively. Comparable 
reductions in overall protein synthesis and the synthesis of 
E-selectin and plasminogen activator inhibitor-1 (PAM) were 
observed. This suggests an effect on general protein synthe­
sis rather than a specific effect of PKC in the signal transduc­
tion pathway, by which TNFa induces VT-1 receptors. Our 
results indicate that TNFa can increase the VT-1 receptors on 
endothelial cells by inducing galactosyl-transferase activity, 
that this action of TNFa mainly occurs via the TNFR-p55; 
and that PKC activation increases expression of VT-1 recep­
tors by a separate mechanism that acts additively to the 
TNFa-induced increase in VT-1 receptors.
© 1995 by The American Society of Hematology.
HE EPID EM IC  FO R M  o f  the hem olytic uremic syn­
drome (HUS) is characterized by hemolytic anemia, 
throm bocytopenia, and acute renal failure. It is m ostly seen 
in young children and has a prodrom al phase of acute, often 
bloody, gastroenteritis .1 Since the beginning o f  the 1980s, it 
has become clear that verocytotoxin (VT)- or Shiga-like 
toxin-producing Escherichia colt infections are the main
show n that purified V T can d am ag e  the endothelium .4"7 The 
functional V T receptor, the glycosphingolipid  globotriao- 
sylcerami.de (GbOse^cer), p lays a crucial role in endothelial 
cell d a m a g e /  This receptor has been found in the human
and on cultured endothelial cells . 10 Recently, we 
have reported that inflam m atory  m ediators, such as tumor 
necrosis factor a  (T N F a)  and in te rleuk in -1 (IL-1), can po-
cause o f this form o f  H U S .2 A family o f  three V Ts has tentiate the toxic effect o f VT-1 to hum an endothelial cells
been described: verocytotoxin -1 (V T-1) or shiga-like toxin 
I (SLTI), verocytotoxin-2 (V T-2) or shiga-like toxin II 
(SLTII) and verocytotoxin-2 variant (V T -2c). ' A lthough the 
exact pathogenesis is still unknow n, endothelial cell dam age, 
predom inantly seen in the glomeruli in the kidney, is be-
by inducing an increase in the GbOse^cer synthesis in these 
ce lls .7 Inflam m atory m ediators are produced and released by 
m onocy tes11 and m esangial cells in v itro , 1211 and may play 
a local role in the kidney. A recent report from Harel et 
a l 1'1 dem onstrated  that SLTI can specifically induce T N F a
lieved to play a central ro le . 1 Several in vitro studies have activity in m ouse kidney. Increased  production o f  the cyto­
kines T N F a , IL -1/3, and IL -6  can  also be found in the media 
o f  cultured hum an m onocytes a fte r stimulation with V T - I . IS 
In this report, we extend our observations and show that 
T N F a  and IL-1 induce specific galactosyl-transferase(s), 
w hich  is (are) necessary  fo r  the synthesis o f  G bO se,eer in 
the endothelial cells.
Recently, two T N F  receptors (TN FR s) have been identi­
fied and cloned, a 55-kD  receptor TN FR -p55 and a 75-kD 
receptor T N F R -p 7 5 . 16 Both receptors are present on human 
endothelial ce lls . 17,18 T he  T N F R -p55  has been shown to be 
involved in the signal transduction o f  T N F a  during the in­
duction of several products o f  endothelial cells, such as E-
and V C A M -1 . 17 T he involvem ent of both TN F 
receptors in the T N F a - in d u c e d  increase in GbOse.,cer syn­
thesis and the role o f  protein k inase  C (PKC) in the induction 
o f  V T receptors in hum an endothelia l cells were studied.
Front Gaubins Laboratorium TNO-PG, Leiden; Pediatric Depart­
ment, Sint Radboiul Hospital, Nijmegen, The Netherlands; anti Hoff- 
mttnn-lM Roche Ltd, Basle, Switzerland.
Submitted May 4, 1994; accepted October 4, 1994.
Supported />v a grant from the Dutch Kulnev Foundation, Grant 
No. ('90.1021.'
Address reprint rei/uests to Victor W.M. van Hinsbergh, PhD, 
Gauhius Laboratory TNO-PG, PC) Box 430, 2300 AK Leiden, The
Netherlands.
The publication costs o f this article were defrayed in part by page 
charge payment. This article must therefore be hereby marked 
“ advertisement”  in accordance witlt IS U.S.C. section 1734 solely to 
indicate this fact.
(n 1995 hy The American Society o f  Hematology,
0006.49 71 m/8503-Ot) I f$J. 00/0
734 Blood, Vof 85, No 3 (February 1), 1995: pp 734-743
TNF INCREASES ENDOTHELIAL GALACTOSYL TRANSFERASE 735
MATERIALS AND METHODS
Male rials. Puri lied VT-1 was prepared in the laboratory of Dr 
M.A. Kurmali (Hospital for Sick Children, Toronto, Canada) (1.2 
mg protein/mL; CI)M, vero-eells: titer 10 ~H to 1() '<,).|U Endotoxin 
content of the VT-1 preparation was less than 0.05 EU/mL by Limu- 
lus anioebocyte lysate assay (E-Toxic; Sigma Chemicals, St Louis, 
MO) at a detection level of 0.05 to 0.10 EU/mL. M l99 medium 
supplemented with 20 mmol/L HEPES was obtained from Flow 
Laboratories (Irvine, Scotland); tissue culture plastics were from 
Costar (Cambridge, MA). A crude preparation of endothelial cell 
growth factor was prepared from bovine brain as described by Ma­
cing el al/’" Human serum was obtained from a local blood bank 
and was prepared from fresh blood of healthy donors, pooled, and 
stored at 4“C; it was not heat-inactivated before use. Newborn calf 
serum (NBCS) was from GIBCO (Grand Island, NY), and it was 
heat-inactivated before use (56"C for 30 minutes). Heparin was pur­
chased from Leo Pharmaceuticals (Weesp, The Netherlands). Peni­
cillin/streptomycin was from Boehringer Mannheim (Mannheim, 
Germany). Human libronectin was a gift from J.A. van Mourik, 
Central Laboratory of the Red Cross Blood Transfusion Service 
(Amsterdam, The Netherlands). Pyrogen-free human serum albumin 
(USA) was purchased from the Central Laboratory of the Red Cross 
Blood Transfusion Service (Amsterdam, The Netherlands). Human 
recombinant TNlvv was a gift from Jan Tavernier (Biogent, Ghent, 
Belgium). The TNFn' preparation contained 2.45 X ] 07 U/rng protein 
and less than 40 ng lipopoiysaecharide (LPS) per mg protein. Human 
recombinant IL-1/3 was a gift from S. Gillis (Immunex, Seattle, 
WA); it had a specific activity of 10K U/mg. The mutant R32W- 
S86T-TNF«, which selectively binds and activates the human 
TNFR-p55, and does not react with the human TNFR-p75, and 
the mutant D143N-A145R-TNF«, which specifically recognizes the 
TNFR-p75, were previously reported.“ The antagonistic monoclonal 
antibody utr-l, specific for the TNFR-p75, and the agonistic mono-
the experiments were used after one to three passages. Human fore­
skin tnicrovascular endothelial cells were used after four to six pas­
sages. The medium was renewed every 2 or 3 days.
Binding o f l2:sl-VT-I to human endothelial cells. VT- 1 was radio- 
labeled with Na125I according to the lodogen procedure.2* Five prepa­
rations of purified VT-1 were iodinated to specific activities ranging 
from 16.2 to 26.8 of protein. All preparations gave
similar results. For the experiment, confluent HUVEC, cultured in 
2-cnr wells, were incubated for indicated times with medium M l 99 
to which the appropriate concentration of the test compounds were 
added. The inhibitory antibody utr-1 and the PKC-inhibitor Ro31- 
8220 were added I hour before the start of the experiment. The 
binding assay was performed as follows: after the incubation period 
at 37°C with the indicated compounds, the endothelial cell cultures 
in 24-well plates were washed with M l99 medium plus 0.1% HSA 
(wt/vol). Subsequently, the cells were incubated for 3 hours with 
1.0 nmol/L I25I-VT1 in M l99 plus 0.1% HSA (wt/vol) at 0°C. After 
the incubation, the supernatant fluid was aspirated, the cells were 
washed live times with M l99 plus 0.1% HSA, and total cell protein 
was solubilized in 400 ¡xh 0.5 mol/L sodium hydroxide at room 
temperature. Radioactivity of the endothelial cells was measured in 
a gamma-counter. Nonspecific binding was determined by assay of 
'-’[-VT-1 binding in the presence of 50-foid excess of unlabeled 
VT-1. Cellular specific binding was determined by subtracting the 
nonspecific binding from the cellular binding of l25I-VT-l deter­
mined in the absence of unlabeled VT-1.
Extraction o f glycolipids. Confluent endothelial cell cultures 
were incubated for 24 hours with or without 20 ng/mL TNFa or 0.5 
ng/mL IL-1/3. Six hours after the start of the incubation, 0.5 
mL "C-glucose or "C-galactose was added to the media. Subse­
quently, after the 24 hours incubation period, the glycolipids were 
extracted as described by Ling wood et al.K In short, the cells were
trypsinized, harvested with ice-cold phosphate-buffered saline 
(PBS), and spun down by a 3-minute centrifugation (3,000 rpm) at 
4°C. The pellet was washed three times with PBS. The pellet was 
finally suspended in PBS, and 20 vol of chloroform/methanol (2:1, 
vol/vol) was added. Cell debris was removed by filtration through 
glass-wool. One volume of water was added to obtain phase separa­
tion. The lower phase was dried and incubated at 37°C for 2 hours 
vino serum albumin (BSA), and Tween 20 were obtained from Sigma in 1 mL 0.4 mol/L KOH in ethanol; 2 vol of chloroform was added
clonal antibody htr-9, specific for the TNFR-p55 were pre 
reported.“  The specific PKC-inhibitor C3 (Ro-31-8220)’-' was a gift 
from Dr G. Lawton (Hoffmann La Roche, Welwyn Garden City, 
UK). The inhibitors 11-7 and HA-1004 were purchased from Seika- 
gaku, Tokyo, Japan). Phorbol 12-myristate 13-acetate (PMA), bo-
Chemical Co. Na,'"’I-iodine, "C-glucose (50 to 60 mCi/mmol) and 
''C-galaciosc (50.3 mCi/mmol) were purchased from Amersham 
(Amersham, UK), lodo-gen iodination reagent was obtained from 
Pierce (Rockford, IL). Chloroform, methanol, and hexane were ob­
tained from Merck (Darmstadt, Germany). Plastic coated silica gel 
FI 500 thin-layer chromatography (TLC) plates were from Schleicher 
and Schtlll (Dassel, Germany). Polyisobutylmethacrylate was ob­
tained from PolySciences (Washington, MD). A standard mixture of 
pure neutral giycosphingolipids containing Gal/il-ICcramklo(Cer)
(CMI1), Gal/.ƒ I -4Glc/i I - I Cor (CDII), Gala 1 -4Gal/i I -4Crlc/31 -1 Cer 
(GbOse,cer), GalNac/f I -.Kialtv 1 -4Gal/II -4Glc/i 1 1 Cer (GbOsc.,cer) 
and GalNaenr I ~3GalNac/i 1 -3Gal« I -4Gul/? I -4Glc/31 -1 Cer (Forss-
mann pentasaccharide) was from Biocarb (Lund, Sweden). X- 
OMAT x-ray film was from Eastman Kodak (Rochester, NY).
Cell culture. Hiulothelial cells from human umbilical vein (HU- 
VHC) and from human foreskin were isolated by collagenase treat- 
ment, cultured, and characteri/.eil as previously d esc r ib ed .* 'T h e  
endothelial cells were seeded in libronectin-coated l()-cnr wells and 
cultured in M l99 medium supplemented with 20 mmol/L HEPES 
(pH 7 .4 ), 10% (vol/vol) human serum (US), 10% (vol/vol) heat- 
inactivated newborn calf scrum, 2 mmol/L L-glutamine, 5 IJ/mL 
heparin, and 150 /jg/ml, crude preparation of endothelial growth
factor under 5% CO. and 95% air at 37“C. When the cells reached
* \
coniliieney, (hey were detached with trypsin/KDTA and seeded in 
2-enr libronectin coated dishes with a split ratio of 1:3. HUVEC in
and the mixture was partioned against 2 vol of water* The lower 
phase was separated and frozen until TLC studies were performed.
Thin-layer chromatography. The lower phase from the extrac­
tion above was dried and resuspended in chloroform/methanol (2 :1, 
vol/vol). Samples were separated on a silica gel TLC plate using 
chloroformrmethanol.water (65:25:4, vol/vol/vol). Standard neutral 
giycosphingolipids, 2 //g of each glycolipid, together with an equal 
volume of unlabeled glycolipid cell-extract, were run on the same 
TLC and afterwards stained by orcinol-spray. After separation, the 
plate was air-dried, and exposed toX-OMAT x-ray film. After devel­
oping the film, the plate was soaked three times for 1 minute in 
0 .01% polyisobutylmethacrylate in hexane and air-dried, followed 
by overnight incubation in PBS supplemented with 1% BSA and
0.05%i Tween 20. Subsequently, the plate was incubated with 50 
mL VT-1 solution (15 nmol/L unlabeled, 1.5 nmol/L ' ’5I-VT-1 in 
PBS supplemented with 1% BSA and 0.05%' Tween 20) for 4 hours 
at 4°C. The plate was extensively washed with 0.05% Tween 20 
and 1 % BSA in PBS, air-dried, and exposed to X-OMAT x-ray film.
Assays. Levels of PAI-1 antigen in endothelial cell-conditioned 
medium were assayed by ELISA (IMULYSE PAI-1) obtained from 
Biopool (Umea, Sweden), according to the manufacturer’s de­
scription.
The presence of E-selectin was determined by cell enzyme-linked 
immunosorbent assay (ELISA) in triplicate wells with HUVEC cul­
tured in libronectin-coated 96-multiwell dishes. After a 5-hour incu-
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bation with 20 ng/mL TNPa (inhibitors added 1 hour before addition 
of TNFa), the amount of E-selectin was determined on fixed cells
by using an anti-E-selectin monoclonal antibody Ena-22,) (gift of Jet 
Leeuwenberg, Maastricht, The Netherlands) and a rat peroxidase- 
labeled antimouse immunoglobulin G (IgG). After development of 
the assay, the optical density was recorded.
Statistics. Experiments were done with at least three different 
cultures of HUVEC, unless otherwise mentioned. Data are given as 
mean ± SEM. Statistical analysis was performed with the Wilcoxon 
test. Statistical significance was accepted for P < .05.
RESULTS
TNFa increases the activities o f
Our a
or IL-
1 (5 causes a protein synthesis-dependent increase in the 
number of VT-1 receptor molecules, the glycosphingolipid 
globotriaosylceramide (GbOse3cer, Gala 1 -4Gal/31 -4Glcj01 -
the increase in GbOse^cer molecules by the cytokines TNFa 
or IL-1/3 is caused by the induction of glucosyl- or galacto- 
syltransferases, HUVEC were incubated with or without the 
cytokines TNFa; or IL-1/3 together with l4C-glucose or l4C- 
galactose for a period of 24 hours. After the incubation- 
period, the l4C-labeled neutral glycosphingolipids were ex­
tracted and separated on TLC. In Fig 1, it is shown that the 
incorporation of 14C-galactose in GbOse3cer and other neu­
tral glycosphingolipids is markedly enhanced after incuba­
tion of the cells with TNFa: and, to a less extent, with IL- 
1/3 (lanes b through d). The presence of GbOse3cer was 
confirmed by the standard sample of neutral glycosphingo­
lipids (lane a) and by incubation of the TLC with l25I-VT- 
1, which specifically binds to GbOse3cer (lanes e through 
g). The increase in the incorporation of 14C-galactose in 
GbOse.icer is parallelled by an increase in 125I-VT-1 binding 
to the GbOse3cer position on the TLC. A similar TNFa-
lCer).7 The biosynthesis of glycosphingolipids occurs via induced increase in l4C-galactose incorporation in GbOse3cer
sequential transfer of sugar moieties from nucleotide sugar 
donors to ceramide. Specific glucosyl- and galactosyltrans- 
ferases are involved in this process. To investigate whether
and other neutral glycosphingolipids was also observed in 
human foreskin microvascular endothelial cells (not shown). 
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Fig 1. Increase of galactose-containing glycoiipids extracted from 1.6 x 106 HUVEC. Confluent HUVEC were incubated for 24 hours with or 
without 20 ng/mL TIMFa or 0.5 ng/mL IL-1/J. Six hours after addition of TNFa, 0.5 /¿Ci/mL 14C-galactose was added to the medium. After the 
incubation-period, glycoiipids of 1.6 x 10s cells were extracted and separated by TLC. Lane a, standard neutral glycosphingolipids, 2 /u.g of 
each glycolipid, visualized by orcinol-spray. Lanes b through d, autoradiograms of 14C-galactose containing endothelial glycosphingolipids. 
Separated glycolipid-extracts of 1.6 x 10® cells treated with no inflammatory mediator (lane b), with 20 ng/mL TNFa (lane c), and with 50 U/ 
mL IL-1/3 (lane d). Lanes e through g, the same TLC was assayed for 125I-VT-1 binding. Autoradiographs of 125I-VT-1 binding to glycolipid- 
extracts of control cells (lane e), treated with 20 ng/mL TNFa (lane f ), or with 50 U/mL IL-1/3 (lane g). 1, galactosylceramide; 2, lactosylceramide;
3, globotriaosylceramide (Gb0se3cer); 4, globotetraosylceramide; 5, Forssman pentasaccharide; and 6, origin of the lane.
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Fig 2. Autoradiogram of 14C-glucose- or ™C-galactose-contaming glycolipid-extracts separated on TLC. Confluent HUVEC treated for 24 
hours without or with 20 ng/mL TNFa  with uC-glucose or uC-gaIactose. Glycolipids of 1.6 x 106 cells were extracted and separated on 
TLC. Lane a, standard mixture of 2 ¿t,g of each neutral glycosphingolipids visualized by orcinol-spray. Lane b, standard mixture of neutral 
glycosphingolipids mixed with unlabeled giycosphingolipid cell-extract, visualized with orcinol spray* 14C-galactose containing glycolipid- 
extract of control cells (lane c) and TNFc*-treated cells {lane d). MC-glucose containing glycotipid»extract of control cells (lane e), ^C-glucose 
containing glycolipid-extract of TI\IFi*-treated cells (lane f ), 1, galactosylceramide; 2 , lactosylceramide; 3# globotriaosylceramide (GbOse3cer); 
4, globotetraosylceramide; 5, Forssman pentasaccharide; and 6, origin of the lane.
14
glucose and "L-gaiaeiose were 
incorporation of ''C-glueose in glycosphingolipids in the 
TNFtt-treated HUVEC were comparable to that in control
Involvement of the two TNF receptors in the TNFa-medi
induce VT-I receptor synthesis in endothelial cells. This was 
confirmed with the agonistic monoclonal antibody I Hr-9, that 
specifically activates the TNFR-p55 (Table 1). However, 
when the effects of wiid-type TNF« and R32W-S86T-TNF« 
were compared, the mutant reached 77% ± 5% of the effect
ated increase in VT receptors. To investigate which of the of the wild-type TNF« (mean ± SEM, P < .05; paired data 
recently cloned TNF receptors, TNFR-p55 and TNFR-p75, 
is involved in the induction of GbOse.eer in human endothe-
of seven cultures, incubated for 24 hours with 20 ng/mL of 
both TNF« forms). Furthermore, it was observed in several
lial cells by TNF«, the binding of l25I-VT-1 was determined time course experiments that, at low concentrations of TNF«
after incubation of HUVEC with wild-type TNF«, the mu­
tant R32W-S86T-TNF«, which recognizes and stimulates 
TNFR-p55 only, or the mutant D 143N-A145R-TNF«, which 
specifically interacts with the TNFR-p75. With concentra­
tions up to 20 ng/mL, R32W-S86T-TNF« induced a coneen-
tration- increase in VT-1 binding, whereas 
D 143N-A145R-TNF« had no effect (Table 1, Fig 3A-C). 
Thus, the sole stimulation of the TNFR-p55 is sufficient to
and its mutant (0,2 ng/mL), the initial increase of VT-1 
receptors induced by the R32W-S86T-TNF« was detectable 
1 or 2 hours later than that by wild-type TNF«. These obser­
vations suggest that wild-type TNF« provides a signal addi­
tional to stimulation of the TNFR-p55, probably via the 
TNFR-p75. This may occur by activation of the TNFR-p55 
via TNFR-p75-mediated signal transduction, or by concen­
tration of TNFa molecules on the cell surface by the TNFR-
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Table 1. Effect of TNF-Receptor Agonists on VT-1 Binding to
Human Endothelial Cells
125I-VT-1 Binding (fmol/105 cells)
Addition 9-h Incubation 24-h Incubation
Control 2.3 ±  0.8 (9) 1.7 ±  0.6 (10)
Wild-type TNFa (20 ng/mL) 7.7 ±  2.6 (9)* 23.2 ±  5.8 (10)+
R32W-S86T-TNF« (20 ng/mL) 5.8 ±  3.8 (5)* 19.7 ±  7.2 (7)*
D143N-A145R-TNF« (20 ng/mL) 2.4 ± 0.2 (3>* 2.2 ±  0.1 (4)*
D143N-A145R-TNF« (200 ng/mL) 2.2 ±  0.1 (2)* 2.0 ±  0.1 (3)*
MoAb htr-9 (10 pg/mL) ND 8.5 ± 1.6 (3)
Specific binding of 1 nmol/L 126I-VT to confluent HUVEC was deter­
mined after a 9- or 24-hour incubation with wild-type TNF«, the mu­
tant R32W-S86T-TNF«, which only activates TNFR-p55, or the mutant 
D143N-A145R-TNF«, which only activates TNFR-p75, or with the 
monoclonal antibody htr-9 (MoAb htr-9), which activates the TNFR- 
p55. Data are expressed as the mean ± SEM of the number of inde­
pendent experiments indicated in parentheses. Statistically signrfi- tion (Fig 5). Desensitization of PKC activity by PM A pre­
cant difference was evaluated by the Wilcoxon test for paired data.
Abbreviation: ND, not determined.
* P < .05 compared with control cells.
t  P < .01 compared with control cells.
$ The control data of these experiments were normalized to the 
mean control value to aid comparability.
stimulation by TNFa:, R32W-S86T-TNF«, or PMA alone 
(Fig 4A). No additional increase in specific VT-l binding 
was seen when PMA was given with D143N-A145R-TNFa, 
as compared with PMA alone (not shown). For comparison, 
the production of PAI-1 was assayed in the conditioned me­
dium of the same cells. As expected, PMA did not alter 
PAI-1 production; addition of 10 nmol/L PMA had a slight 
stimulatory effect on the TNFa-induced increase in PAI-1 
production (Fig 4B).
To evaluate the role of PKC activity in the PMA- and 
TNFa-induced increases in VT-1 receptors, HUVEC were 
preincubated for 20 hours with 10 (' mol/L PMA, washed 
three times and subsequently incubated for another 24 hours
with Wher
enhanced the induction of VT-1 receptors under control con­
ditions, its effect disappeared after homologous desensitiza-
treatment reduced TNFa-induced increase in VT-1 
only by 24% ± 9%. A similar decrease (22% ± 11%) was 
seen in TNFa-increased PAI-1 synthesis of these cells (302 
± 19 v 392 ± 18 ng PAI-1/24 h/105 cells in TNFa-stimulated
p75, so that the binding to the TNFR-p55 is facilitated by
passing.31' When we added the TNFR-p75-stimulating 
mutant with the TNFR-p55-stimulating mutant to the cells, 
no further increase in VT-1 binding was observed as com­
pared with the TNFR-p55 mutant alone (Fig 3D). Therefore, 
TNFR-p75-mediated enhancement of the TNFR-p55 activity 
is unlikely. Similarly, when the TNFR-p75-binding mutant 
D143N-AI45R-TNFcf was added simultaneously with wild- 
type TNFa:, no reduction of the VT-1 binding was observed 
(not shown). However, when the cells were preincubated 
with the monoclonal antibody utr-1, that blocks the TNFR- 
p75, a reduction in the effect of TNF« on VT-1 binding was 
observed after 9 hours of incubation (Table 2). After 24 
hours of incubation, this effect was still observed at moderate 
concentrations of TNF« (2 ng/mL), but not at high concen­
trations (20 ng/mL TNFcv) (not shown). This is compatible 
with a ligand passing effect, which vanishes at saturating 
TNF concentrations. The utr-1 monoclonal antibody had no 
effect on the ability of the TNFR-p55-stimulating R32W- 
S86T-TNF« to induce VT-1 receptors (Table 2). This makes 
an aspecilic effect of the utr-1 antibody unlikely.
Involvement o f PKC in the induction o f VT~1 receptors. 
The PKC activator phorbol myristate acetate (PMA) and the 
PKC inhibitors Ro31-8220 and H-7 were used to study the 
role of PKC in the induction of the VT-1 receptor GbOse^cer. 
Stimulation of PKC by PMA enhanced the specific binding 
of VT-1 to a moderate extent in comparison with TNFa 
(Fig 4A). In six different HUVEC cultures 10 nmol/L PMA 
stimulated specific l25I-VT-l binding 4 ± 1-fold, while 20 
ng/mL TNFa induced a 16 ± 3-fold increase in the same 
cells (mean ± SEM, 24-hour incubation). When HUVEC 
were incubated with PMA and TNFa: or R32W-S86T-TNFa; 
simultaneously, the increase of VT-1 receptors was consider­
ably larger than that obtained by TNFcv or R32W-S86T- 
TNF« alone, and the induction occurred faster than after
cells pretreated with I0~(’ mol/L PMA or control medium, 
respectively, three independent cultures).
Comparable results were obtained with PKC inhibitors. 
While the inhibitor Ro31 -8220 at 3 /¿mol/L completely sup­
pressed the effect of PMA on VT-1 binding (Fig 6, inset), 
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Fig 3. Effect of various concentrations of wild-type TNFa: (A), the 
TI\IFR-p55-specific mutant R32W-S86T-TNF<* (B), and the TNFR-p75- 
specific mutant Dl43N-A145R-TNFa (C) on the specific 125l-VT-bind- 
ing to HUVEC. Cells were incubated with a low concentration range 
wild-type TNFo? or TIMFa mutant for 6, 12, or 24 hours, respectively 
(■ control cells, □ 0.2 ng/mL, A 0.4 ng/mL, O 0.8 ng/mL, •  2 ng/ 
mL). Concentrations of 20 or 200 ng/mL D143N-A145R-TNF<* showed 
the same binding as 2 ng/mL D143N-A145R-TNF£*. (D) 125I-VT binding 
to endothelial cells incubated for 6, 12, or 24 hours with 2 ng/mL 
R32W-S86T-TNFa (•) together with D143N-A145R-TNFa at 0.4 ng/ 
mL (A), 4 ng/mL (0), or 20 ng/mL (V); (■ control cells).
TNF INCREASES ENDOTHELIAL GALACTOSYL TRANSFERASE 739
TIMFa-lnduced Increase of VT-1 Receptors
Table 2. Effect of the TNFR-p75 Blocking Antibody utr-i on the thelial cells, and that protein synthesis was necessary tor
this induction.7 Here, we have demonstrated that the I N.Hr- 
induced increase in VT-1 receptors is due to an increase in 
galactosyl-transferase activity in the endothelial cell. I his
induction occurs predominantly via the TNFR-p55 by a 




Culture Culture Culture % Effect utr-1 
1 2 3 (mean ± SEM)
None 0.6 0.4 6.5 100
utr-1 (10 jug/mL) 0.6 0.5 6.7 108 ± 6
TNFa (2 ng/mL) 3.2 3.1 19.4 100
TNFa (2 ng/mL) + utr-1
(10 pg/ml) 1.6 2.2 15.4 66 ± 9
TNFa (20 ng/mL) 4.9 4.7 26.1 100
TNFa (20 ng/mL) + utr-1
(10 /zg/mL) 2.7 3.6 22.6 73 ± 9
R32W-S86T-TNFa (20 ng/mL) 2.6 2.9 20.9 100
R32W-S86T-TNFa (20 ng/mL)
+ utr-1 (10 //,g/mL) 2.3 2.6 21.5 93 ± 5
Effect of the antagonistic monoclonal antibody utr-1, specific for 
TNFR-p75 on the 12BI-VT-1 binding to three different cultures of con­
fluent HUVEC. Cells were treated for 9 hours with TNFa or R32W- 
S86T-TNFa in the absence or presence of the antibody utr-1. The 
antibody utr-1 was added to the cells 1 hour before addition of TNFa; 
or its mutant. After the 9-hour incubation period, the media above 
the cells were removed and 1 nmol/L 125I-VT-1 was added to the cells 
as described in Materials and Methods. Data are also expressed as 
the percentage toxin binding as compared with their counterparts, 
which were not incubated with utr-1 (mean ± SEM for the three exper­
iments).
PKC activation.
The kidney contains a relatively high amount of glyco-
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addition of TNFa or R32W-S86T-TNF« by 48% ± 9% 
(Figs 6 and 7A). Incubation of the cells with another PKC 
inhibitor, H-7 (30 ¿¿mol/L), gave the same results as obtained 
with Ro31-8220, whereas a structural homologue of H-7, 
HA-1004 (30 /¿mol/L), which has a similar protein kinase 
A-inhibiting capacity as H-7, but much less PKC-inhibiting 
activity, was inactive in this respect (Fig 7A). However, Ro- 
31-8220 (3 /¿Mol/L) and H-7 (30 /¿mol/L), but not HA-1004 
(30 ¿¿mol/L), inhibited TNFa-induced expression of PAI-1 
and E-selectin, a protein of which the TNFa induction is not 
dependent on PKC activity,31”’2 to a comparable extent (Fig 
7B,C). Furthermore, the reduction in TNFa-induced VT-1 
receptors by these inhibitors was paralleled by a comparable 
reduction in overall protein synthesis, as estimated from the 
incorporation of ’5S-methionine in proteins (Fig 7D). In the 
absence of TNFa, these inhibitors affected protein synthesis 
by less than 10% (not shown).
These findings indicate that activation of PKC 
the stimulation of VT-1 receptors by PMA. They suggest 
that PKC is not directly involved in the TNFa-dependent 
signaling pathway causing induction of VT-1 receptors, but 
can contribute via another pathway additionally to the effect 
of TNFa on the expression of VT-1 receptors.
DISCUSSION
The inflammatory mediators TNFa and IL-1 increase the 
toxicity of VT and the closely related shiga toxin for human 
endothelial cells.5'7 Previously, we have demonstrated that 
TNFa and IL-1 increase the number of VT-1 






















antigen (B) by confluent human endothelial cells incubated with 10 
nmol/L phorbol ester PMA (closed symbols) or In it* ab ttftM  (open 
symbols). HUVEC were simultaneously Incubated with 20 ng/ml* 
TNFc* (N, □) or 20 ng/ml R32W*S86T-TMFtr (A, A) for th<l Indicated 
time Intervals. The control cells are indicated with clrclo?*. Mo dHf&r* 
ence in 128I-VT-1 binding and PAt-1 production wag ob$#rv#d wh©n 
D143 W-A145R-TNFa was incubated togothitr with 10 nmol/L PMA m  
compared with PMA alone (data not shown)*














Fig 5. Effect of PKC desensitization on the induction of VT-1 recep­
tors by TNFa and phorbol ester PMA. HUVEC were preincubated for 
20 hours in culture medium supplemented with 1(T6 mol/L PMA (■)
or in the same medium without PMA (H). Subsequently, the cells 
were washed three times and incubated for 24 hours in culture me­
dium supplemented with 20 ng/mL TNFa, 10 nmol/L PMA or without 
addition (control), after which specific binding of 1Z5I-VT-1 to the cells 
was determined. The data are the mean ± SEM of three different 
HUVEC cultures.
synthesis of neutral cellular glycolipids. A confirmation of 
the induction of galactosyl-transferase(s) at the mRNA level 
is not yet possible, because ceramide glycosyl-transferases 
have not been cloned, with the exception of a brain-specific 
ceramide uridine-5 '-diphosphate (UDP)-galactosyl trans­
ferase, which was reported very recently.39 The physiologic 
meaning of the induction of galactosyl-transferase(s) in in­
flammation is not known. On the basis of sequence homolo­
gies of verotoxins and the a-interferon receptor, Lingwood 
et al40 has suggested that GbOse3cer may act as an accessory 
molecule for the a-interferon receptor. Hence, the altered 
synthesis of glycosphingolipids may play a role in the modu­
lation of the inflammatory process. In this respect, it is of 
interest to note that another inflammatory mediator, y-inter- 
feron shifts the cellular distribution of glycosphingolipids 
towards the surface of endothelial cells.41
TNFa acts on cells via two receptors, TNFR-p55 and 
TNFR-p75, to which it binds with similar affinity.16 Both
receptors are expressed on unstimulated HUVEC, 17,18 but
this study shows that activation of TNFR-p55 by TNFa is 
sufficient for the induction of GbOse3cer in human endothe­
lial cells. This finding corresponds well with the TNFa- 
induced expression in endothelial cells of E-selectin, 
VCAM-1, ICAM-1, interleukin-8, interleukin-6, and granu­
locyte-macrophage colony-stimulating factor (GM-CSF), 
which are under TNFR-p55 control.17,18,42 However, the 
TNFR-p55 selective mutant was always slightly less potent
tubular epithelial cells.33,34 It is also encountered in the glo­
meruli of children younger than 2 years old,35 but the cellular 
distribution in the glomeruli has not yet been resolved. In 
the glomeruli of kidneys of adults and children older than 
two years, no significant expression of GbOse3cer was 
found.35 This suggests a developmental shift in the synthesis 
of glycosphingolipids in glomerular cells. In cultured cells, 
glycosphingolipids play a role in cell growth and cell differ­
entiation,33 but little is known about the physiologic role of 
these glycosphingolipids in various cell types of the intact 
kidney. Bacterial exotoxins use specific glycolipids as recep­
tors to enter eukaryotic cells where they interfere with the 
metabolism of the cell.36,37 In the case of VT, the toxicity is 
primarily caused by inhibition of the interaction of elonga­
tion factor-1 with the ribosome, which results in a complete 
inhibition of protein synthesis.38 Previous studies have dem­
onstrated that the sensitivity of endothelial cells for the toxin 
is determined by the number of toxin receptors, ie, GbO-
5‘7 and that the number of the VT-1 receptors is mark­
edly increased after exposure of endothelial cells to inflam­
matory mediators.7 We have suggested that local generation 
of inflammatory mediators may increase the sensitivity of 
the kidney and, in severe cases of HUS, that of the endothe­
lium of other organs to VT.
Our present data demonstrate that TNFa, and also IL-1 /3, 
induce an enhanced production of neutral galactose-con­
taining glycolipids by an increase in galactosyl-transferase 
activity. This explains the increase in GbOse3cer molecules 
found on TNFa-stimulated endothelial cells.5"7 To our 
knowledge, this is the first report indicating an inductive 


































Fig 6. Specific binding of l-VT-1 to HUVEC incubated for 8, 16, 
or 24 hours with 20 ng/mL TNFa (□), 20 ng/mL R32W-S86T-TNFa 
(A) or without addition (O), The PKC inhibitor Ro31~8220 (3 /xmol/L) 
was added 1 hour before the start of the experiment to the cells 
and remained present during the incubation period (closed symbols). 
Results are the mean ± SEM of three independent experiments. Inset: 
Specific binding of 125I-VT-1 to confluent HUVEC treated with 10 
nmol/L PMA in the presence of 3 ¿imol/L Ro31-8220 (T) or without 
inhibitor (V).





















à i n a i l i  i l l




















0 1 10 100



















« I  É t d l H i i l






















1 10 1 0 0
Inhibitor (pmol/L) Inhibitor (mmol/L)
Fig 7. (A) Concentration dependency of the inhibition of TNFa-induced 1ZBI-VT-1 binding to HUVEC by PKC inhibitors. HUVEC were preincu-
bated for 1 hour with various concentrations of Ro31-8220 {■), H-7 (•), or HA-1004 (A) and incubated for 24 hours in the presence of these 
inhibitors and 20 ng/mLTNF«. Subsequently, the binding of 1 nmol/mL 125I-VT-1 was determined. (B) Production of PAI-1 antigen by the same 
cells during the 24-hour incubation with inhibitors. (C) Expression of E-selectin by HUVEC after 5 hours exposure to 20 ng/mL TIM Fa and the 
indicated inhibitors. E-selectin was assayed by cell ELISA as described in Materials and Methods. (D) Incorporation of 3SS-methionine in 10% 
TCA-precipitable proteins7 during a 24-hour incubation with TNFa and the various inhibitors, indicated in (A). The values represent the mean 
± SEM of three to five independent HUVEC cultures.
than the wild-type TNFa. While activation of TNFR~p75 by 
D143N-A145R-TNFa mutant had no effect on GbOse;!cer 
synthesis, blocking of TNFR~p75 by the monoclonal anti­
body utr-1 reduced the TNFa-induced increase in VT-1 re­
ceptors, in particular, at low TNFa concentrations and at 
early time points. Because simultaneous stimulation of both
on to the TNFR-p55. Similar observations have been made 
regarding the TNFa-induced expression of a2-integrins17 
and the TNFa-induced synthesis of E-selectin.Ili
A complex cascade of signal transducing events, including 
activation of the nuclear transcription factor NF-/cB is proba­
bly involved in the induction of various proteins by TNFa:
TNF receptor types by two TNFa mutants did not enhance in endothelial cells.43 PKC activity has been reported to be 
VT-1 receptor expression more than obtained by stimulation needed for the induction of some TNFa-induced proteins, 
of the TNFR-p55, it is unlikely that an intracellular signal The TNFa-induced synthesis of urokinase4'1 and the adhesion
molecule VCAM-13' can be reduced by inhibitors of PKC, 
whereas these inhibitors do not affect the TNFa-induced 
synthesis of E-selectin,31,32 ICAM-1,32 and PAI-1.44,45 Our
generated via the TNFR-p75 enhanced TNFR-p55 activity 
or TNFR-p55-mediated signals. Our findings are consistent 
with the hypothesis of Tartaglia et al, K> who proposed that
TNFR-p75 can concentrate the TNFa molecules at the cell- data indicate that the TNFa-induced increase of the synthesis 
surface, thereby facilitating the TNFa molecule to be passed of VT-1 receptors does not require PKC activity. This con-
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elusion is based on the observations that heterologous desen­
sitisation by PMA did not specifically reduce the TNFa- 
dependent increase in VT-1 binding, whereas homologous 
desensitization entirely prevented an increase of VT-1 recep­
tors by PMA. In the presence of TNFct, the PKC inhibitors 
Ro31-8220 and H-7, but not the structural analogue HA- 
1004, reduced VT-1 receptor expression to a similar extent 
as that of E-selectin and PAI-1, probably as the result of a 
generally reduced protein synthesis. This suggests that under 
our experimental conditions PKC activity can become a lim­
iting factor in protein synthesis in endothelial cells exposed 
to TNFa.
Activation of PKC by itself causes a moderate increase 
in VT-1 receptors, and as such, adds to the TNFa-induced 
increase in VT-1 receptors. It is not yet known whether the 
effect of PMA on VT-1 binding is caused by an increased 
insertion of GbOse3cer-containing caveolae in the plasma 
membrane after activation of PKC,46 or by an increased syn­
thesis of VT-1 receptors, similar to what happens after acti­
vation of endothelial cells by TNFa. In the latter case, the 
induction of galactosyl transferase activity, which underlies 
the increase in VT-1 receptors, behaves similarly as the in­
duction of E-selectin, which can also be induced by PKC 
activation by a pathway that is different from the TNFa- 
induced expression.31-32
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